Paper Details

  1. Home
  2. Paper Details

Atomoxetine and fesoterodine combination improves obstructive sleep apnoea severity in patients with milder upper airway collapsibility.

Author: AzarbarzinAli, CalianeseNicole, GellLaura K, LabarcaGonzalo, MessineoLudovico, SandsScott A, Taranto-MontemurroLuigi, VenaDan, WangTsai-Yu, WellmanAndrew, YangHyung Chae

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.

Overview

Atomoxetine is a medication for attention-deficit/hyperactivity disorder (ADHD). It has been shown to improve sleep apnoea when combined with oxybutynin, a medication for overactive bladder. This study investigates whether a combination of atomoxetine and a newer medication for overactive bladder, fesoterodine, can also help improve sleep apnoea.
Paper Details　
Original Abstract of the Article :
The combination of the noradrenergic atomoxetine plus the anti-muscarinic oxybutynin acutely increased genioglossus activity and reduced obstructive sleep apnoea (OSA) severity. However, oxybutynin has shorter half-life than atomoxetine and side effects that might discourage long-term usage. Accordi...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/35811347

データ提供：米国国立医学図書館（NLM）

Combating Obstructive Sleep Apnea with Atomoxetine and Fesoterodine

This research ventures into the realm of obstructive sleep apnea (OSA), a sleep disorder that disrupts restful sleep and can have serious health consequences. Think of OSA as a desert sandstorm that chokes the airways, making it difficult to breathe. The study investigated the combination of atomoxetine and fesoterodine, two medications that work on different pathways in the body, aiming to find a more effective treatment for OSA. Their findings suggest that this combination could potentially improve OSA severity and reduce the need for invasive treatments.

Atomoxetine and Fesoterodine: A Potential Breakthrough for OSA

This study explores a novel combination therapy for obstructive sleep apnea, offering a potential solution for patients struggling with this condition. The study found that the combination of atomoxetine and fesoterodine could potentially improve OSA severity and reduce the need for invasive treatments, suggesting a promising avenue for managing OSA.

Getting a Good Night's Sleep: A Foundation for Health

OSA can have significant health consequences, including daytime sleepiness, cardiovascular problems, and reduced quality of life. If you suspect you might have OSA, it's important to consult with a healthcare provider. Lifestyle modifications, such as weight loss, avoiding alcohol, and smoking cessation, can also be beneficial in managing OSA.

Dr.Camel's Conclusion

This research explores a novel combination therapy for obstructive sleep apnea, offering a potential breakthrough for managing this condition. It highlights the importance of ongoing research in developing new and effective treatments for OSA.
Date :
  1. Date Completed 2022-10-18
  2. Date Revised 2023-11-02
Further Info :

Pubmed ID

35811347

DOI: Digital Object Identifier

NIHMS1884820

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.